What is Pfizer’s Women’s Viagra?

Pfizer doesn’t currently market a drug specifically branded as “Women’s Viagra.” The company’s research into female sexual dysfunction focused on flibanserin, marketed under the brand name Addyi.

Addyi differs significantly from Viagra (sildenafil), which treats erectile dysfunction in men by increasing blood flow to the penis. Addyi affects brain chemistry, targeting neurotransmitters believed to influence sexual desire in women. It’s important to note this distinction: Addyi addresses a different aspect of sexual health than Viagra.

Before considering Addyi, consult your doctor. It’s prescribed only to premenopausal women with hypoactive sexual desire disorder (HSDD) and isn’t suitable for everyone. It carries potential side effects, including nausea, dizziness, and drowsiness, and may interact with other medications. Your physician will assess your medical history and determine if Addyi is appropriate for your specific situation.

Drug Target Mechanism Target Audience
Viagra (Sildenafil) Erectile Dysfunction (men) Increased blood flow Men with ED
Addyi (Flibanserin) Hypoactive Sexual Desire Disorder (HSDD) (women) Neurotransmitter modulation Premenopausal women with HSDD, after doctor consultation

Remember to discuss your sexual health concerns openly with your doctor for personalized advice and treatment options.